InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report) traded down 1.6% during trading on Monday . The stock traded as low as C$4.13 and last traded at C$4.19. 17,035 shares were traded during mid-day trading, a decline of 42% from the average session volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Trading Down 1.6 %
The company has a market capitalization of C$33.73 million and a P/E ratio of -2.77. The business has a fifty day simple moving average of C$4.19. The company has a current ratio of 2.13, a quick ratio of 1.45 and a debt-to-equity ratio of 8.48.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- What Does the Consumer Price Index Measure?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Are Penny Stocks a Good Fit for Your Portfolio?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Invest in Artificial Intelligence
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
